Back to results
US 11,517,574 B2Granted
Linezolid formulations
AssigneePersica Pharmaceuticals Ltd.
InventorsLloyd Czaplewski, Sarah Guest
Life of this patent
Estimating the term…
Abstract
The present invention relates to injectable, thermosensitive hydrogel compositions comprising linezolid for relieving and/or treating chronic low back pain (CLBP).
Claims14
An injectable pharmaceutical formulation comprising:
- (a) 2.5% to 20% of linezolid Form II by weight of the formulation,
- (b) a thermosensitive hydrogel comprising 9.5% to 17% poloxamer 407 by weight of the formulation and 14% to 59% iohexol by weight of the formulation, and optionally
- (c) at least one pharmaceutically acceptable excipient,
- wherein linezolid Form II forms a suspension in the thermosensitive hydrogel and has particle size distribution of D90≤10 μm.
1 more element
An injectable pharmaceutical formulation comprising 2.5% to 20% linezolid Form II by weight, 17% to 30% iohexol by weight, and 10.8% to 12.8% poloxamer 407 by weight of the formulation, wherein linezolid Form II forms a suspension.
An injectable linezolid formulation comprising:
- (a) a linezolid Form II powder,
- (b) a thermosensitive hydrogel comprising 9.5% to 17% poloxamer 407 by weight of the formulation and 14% to 59% iohexol by weight of the formulation, and optionally
- (c) at least one excipient,
- wherein said linezolid formulation is prepared through the method comprising:
- (i) milling linezolid Form II to a defined powder with particle size distribution of D90≤10 μm,
- (ii) preparing a unit of linezolid powder from step (i) and sterilizing the preparation,
- (iii) preparing and sterilizing the thermosensitive hydrogel comprising poloxamer 407 and iohexol, and
- (iv) suspending said linezolid Form II powder from step (ii) in the thermosensitive hydrogel from step (iii).
5 more elements
A kit comprising:
- (a) a linezolid Form II powder with particle size distribution of D90≤10 μm, and
- (b) a thermosensitive hydrogel comprising 9.5% to 17% poloxamer 407 by weight and 14% to 59% iohexol by weight,
- wherein the linezolid Form II powder is at an amount to give a concentration of 2.5% to 20% of linezolid by weight.
Dependencies are inferred from the claim text.